🇺🇸 FDA
Pipeline program

Placebo to Pembrolizumab, CISPLATIN , KEYTRUDA 25 mg/mL concentrate for solution for infusion

MK-3475-A18

Phase 3 small_molecule active

Quick answer

Placebo to Pembrolizumab, CISPLATIN , KEYTRUDA 25 mg/mL concentrate for solution for infusion for Locally Advanced Cervical Cancer is a Phase 3 program (small_molecule) at Merck Sharp and Dohme with 1 ClinicalTrials.gov record(s).

Program details

Company
Merck Sharp and Dohme
Indication
Locally Advanced Cervical Cancer
Phase
Phase 3
Modality
small_molecule
Status
active

Clinical trials